Results 21 to 30 of about 5,256,367 (214)

Who responds to a placebo? Factors associated with response to placebo during a double-blind randomised controlled trial [PDF]

open access: yes, 2020
INTRODUCTION: The placebo effect, a desirable outcome resulting from a person’s expected and/or learned response to a treatment or situation, may significantly influence the interpretation of double-blind, randomised controlled trials (RCT). High placebo
Hurst, P., Coleman, D., Saunders, S.
core  

Comparison of indirect treatment methods in migraine prevention to address differences in mode of administration

open access: yesJournal of Comparative Effectiveness Research, 2023
Aim: Indirect treatment comparisons (ITCs) are anchored on a placebo comparator, and the placebo response may vary according to drug administration route.
Howard Thom   +4 more
doaj   +1 more source

Placebo response in trials with patients with anxiety, obsessive-compulsive and stress disorders across the lifespan: a three-level meta-analysis

open access: yesBMJ Mental Health, 2023
Question Randomised controlled trials assessing treatments for anxiety, obsessive-compulsive and stress-related disorders often present high placebo response rates in placebo groups.
Pim Cuijpers   +10 more
doaj   +1 more source

Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression [PDF]

open access: yes, 2012
Background: Randomized, double-blind, placebo-controlled trials constitute the gold standard in clinical research when testing the efficacy of new psychopharmacological interventions in the treatment of major depression.
Berger Michael   +29 more
core   +2 more sources

When Your Doctor “Gets It” and “Gets You”: The Critical Role of Competence and Warmth in the Patient–Provider Interaction

open access: yesFrontiers in Psychiatry, 2019
Background: Research demonstrates that the placebo effect can influence the effectiveness of medical treatments and accounts for a significant proportion of healing in many conditions. However, providers may differ in the degree to which they consciously
Lauren C. Howe   +2 more
doaj   +1 more source

Modeling of the Placebo Response in Parkinson’s Disease

open access: yes, 2021
peer reviewedObjective: The objective of this study was to investigate the predictability of the placebo response in Parkinson’s disease (PD) subjects participating in a randomized clinical trial (RCT). Background: The magnitude and the variability of
Garraux, Gaëtan   +7 more
core  

Placebo and the law of identification

open access: yesFrontiers in Psychiatry
Thousands of essays and studies have been published on placebo and nocebo. Yet, despite this plethora of information, we are not much closer to a comprehensive understanding of the fundamental mechanism producing placebo and nocebo effects than we were ...
Steve F. Bierman   +2 more
doaj   +1 more source

Dietary nitrate modulates cerebral blood flow parameters and cognitive performance in humans: A double-blind, placebo-controlled, crossover investigation [PDF]

open access: yes, 2015
Nitrate derived from vegetables is consumed as part of a normal diet and is reduced endogenously via nitrite to nitric oxide. It has been shown to improve endothelial function, reduce blood pressure and the oxygen cost of sub-maximal exercise, and ...
Haskell, Crystal   +9 more
core   +1 more source

Hype or hope? High placebo response in major depression treatment with ketamine and esketamine: a systematic review and meta-analysis

open access: yesFrontiers in Psychiatry
BackgroundKetamine and esketamine offer a novel approach in the pharmacological treatment of major depressive disorder (MDD). This meta-analysis aimed to investigate the placebo response in double-blind, randomized controlled studies (RCTs) on patients ...
Alexandros Matsingos   +7 more
doaj   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

open access: yesMolecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy